Federal grants to Aqualung Therapeutics, Corp
Aqualung Therapeutics, Corp in Tucson, Florida received $9.8 million in federal grants from fiscal 2021 to 2025, across 7 awards. Its largest program was Cardiovascular Diseases Research, with $7.3 million. In fiscal 2025 more was taken back from its awards than added, a net -$257,707.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$9.8 million
- Awards7
- Awarded in FY 2025-$257,707
- Largest award$2.5 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.8 million |
| FY 2022 | 4 | $1.8 million |
| FY 2023 | 3 | $3.3 million |
| FY 2024 | 3 | $3.3 million |
| FY 2025 | 1 | -$257,707 |
Programs that fund Aqualung Therapeutics, Corp
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 5 | $7.3 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $2.2 million |
| Allergy and Infectious Diseases Research | 1 | $284,699 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 7 | $9.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A randomized phase 2A clinical trial pioneering the utility of an enampt-reducing therapy in ards/vili: the puerta trial - abstract the serious unmet need to address the excessive mortality observed in patients with acute respiratory distress syndrome (ARDS) has been brought sharply into focus by th | Cardiovascular Diseases Research | September 8, 2023 | $2.5 million |
| Targeting the enampt/TLR4 pathway to reduce inflammatory bowel disease severity - abstract inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 sttr application focuses on a highly nov | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 19, 2022 | $2.2 million |
| Enamptortm: a humanized mab to reduce the severity of radiation pneumonitis and fibrosis | Cardiovascular Diseases Research | June 1, 2021 | $2.0 million |
| Preclinical development of a novel enampt-neutralizing mab for pulmonary hypertension - abstract pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 fast track sttr application focuses | Cardiovascular Diseases Research | August 29, 2022 | $1.9 million |
| Novel therapeutic antibody targeting of extracellular nampt in ventilator-induced lung injury (VILI) | Cardiovascular Diseases Research | April 23, 2021 | $750,000 |
| Targeting ENAMPT-TLR4 signaling with the novel ALT-100 mab to slow ipf progression - abstract: there is a major unmet need to identify novel therapies for idiopathic pulmonary fibrosis (IPF), a rapidly pro- gressing fibrotic lung disease often resulting in fatal respiratory failure. Current ipf drug | Allergy and Infectious Diseases Research | September 17, 2025 | $284,699 |
| Targeting the p selectin pathway to improve ards survival - abstract acute respiratory distress syndrome (ARDS) is a critical illness with 30- 40% mortality and currently there are no fda-approved therapies. Quell pharma and aqualung therapeutics have developed a recombinant soluble, cell-free form | Cardiovascular Diseases Research | September 22, 2022 | $259,613 |
Questions people ask
How much federal grant money does Aqualung Therapeutics, Corp get?
$9.8 million in 7 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Aqualung Therapeutics, Corp the most?
The Department of Health and Human Services, with $9.8 million in 7 awards.
What is Aqualung Therapeutics, Corp's largest federal grant?
$2.5 million under Cardiovascular Diseases Research, with its first action in the period on September 8, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Aqualung Therapeutics, Corp?
Its largest are Cardiovascular Diseases Research, Diabetes, Digestive, and Kidney Diseases Extramural Research and Allergy and Infectious Diseases Research.
Largest federal grant recipients in Florida · Federal grants in Florida